1XU Stock Chart & Stats
€0.02
€0.00(0.00%)
At close: 4:00 PM EDT
€0.02
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.02 - €0.10
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€516.75K
Enterprise Value€1.06
Total Cash (Recent Filing)€321.83K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.72
Next Earnings
Oct 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding13,858,926
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.72
Price to Sales (P/S)0.00
P/FCF Ratio-3.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetThe absence of reported debt limits interest obligations and reduces refinancing pressure, giving the company greater financial flexibility than a similarly loss-making business with leverage. This structure may help preserve strategic options while development activities continue.
Improved LossesAlthough the company remains unprofitable, the substantial reduction in losses from the 2021–2022 extremes indicates some improvement in cost absorption or operating discipline. If sustained, lower losses could extend financial runway and reduce the pace of capital consumption.
Focused Therapeutic StrategyA defined focus on psychedelic-assisted therapies gives the business a clear development strategy centered on substantial unmet needs in addiction and mental-health care. Concentration in a specific therapeutic area can support coherent research priorities and regulatory planning.
Bears Say
No Recent RevenueZero recent revenue shows that the company has not yet established a commercial income stream to support operations. This leaves the business dependent on advancing development programs toward future medical use, with limited evidence of near-term self-funded growth.
Persistent UnprofitabilityRecurring operating and net losses indicate that the current business model has not reached sustainable profitability. Continued losses can erode equity, constrain investment in development programs, and make long-term progress increasingly dependent on obtaining additional capital.
Ongoing Cash BurnPersistent negative operating and free cash flow means the company is consuming cash rather than generating funds internally. The renewed deterioration in 2024 and continued burn in 2025 increase the likelihood that external funding will remain necessary to sustain operations.
Entheon Biomedical News
1XU FAQ
What was Entheon Biomedical’s price range in the past 12 months?
Entheon Biomedical lowest stock price was €0.01 and its highest was €0.10 in the past 12 months.
What is Entheon Biomedical’s market cap?
Entheon Biomedical’s market cap is €516.75K.
When is Entheon Biomedical’s upcoming earnings report date?
Entheon Biomedical’s upcoming earnings report date is Oct 22, 2026 which is in 21 days.
How were Entheon Biomedical’s earnings last quarter?
Entheon Biomedical released its earnings results on Jul 20, 2026. The company reported €0.011 earnings per share for the quarter.
Is Entheon Biomedical overvalued?
According to Wall Street analysts Entheon Biomedical’s price is currently Overvalued.
Does Entheon Biomedical pay dividends?
Entheon Biomedical does not currently pay dividends.
What is Entheon Biomedical’s EPS estimate?
Entheon Biomedical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Entheon Biomedical have?
Entheon Biomedical has 13,858,926 shares outstanding.
What happened to Entheon Biomedical’s price movement after its last earnings report?
Entheon Biomedical reported an EPS of €0.011 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Entheon Biomedical?
Currently, no hedge funds are holding shares in DE:1XU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Entheon Biomedical
Entheon Biomedical Corp. operates as a biotechnology research and drug development company. It engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use disorders. The company serves physicians, clinics, and licensed psychiatrists in Canada, the United States, and European Union. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.
Technical Analysis
BetterLife Pharma
―
HAVN Life Sciences
―
MYND Life Sciences
―
Universal Ibogaine Inc
―
Mindbio Therapeutics Corp.
―